Phase IIb trials expand on Phase IIa findings to confirm efficacy in a larger patient population and further evaluate safety. This phase serves as the foundation for pivotal Phase III studies and helps refine inclusion criteria, endpoints, and trial logistics.
With SCIRENT, you move into Phase III with robust data and a trial design optimized for success.
We are a specialized cardiovascular CRO with a deep understanding of the regulatory, clinical, and operational landscape. Whether you’re developing a novel device, diagnostic, or drug – we bring the expertise, network, and flexibility you need at every stage of development.
How can we help you? We will get in touch shortly.
